Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Cash from Financing (Quarterly): 2.032M for Sept. 30, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 2.032M |
| June 30, 2023 | -1.039M |
| March 31, 2023 | 26.62M |
| December 31, 2022 | 5.389M |
| September 30, 2022 | 0.101M |
| June 30, 2022 | 0.052M |
| March 31, 2022 | 0.83M |
| December 31, 2021 | 0.047M |
| September 30, 2021 | 0.38M |
| June 30, 2021 | 2.954M |
| March 31, 2021 | 108.14M |
| December 31, 2020 | 3.241M |
| Date | Value |
|---|---|
| September 30, 2020 | 1.069M |
| June 30, 2020 | 0.101M |
| March 31, 2020 | 0.265M |
| December 31, 2019 | 0.525M |
| September 30, 2019 | 0.099M |
| June 30, 2019 | 0.318M |
| March 31, 2019 | 70.51M |
| December 31, 2018 | 68.24M |
| September 30, 2018 | 20.06M |
| June 30, 2018 | 0.022M |
| March 31, 2018 | 0.01M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.039M
Minimum
Jun 2023
108.14M
Maximum
Mar 2021
8.396M
Average
0.4525M
Median
Cash from Financing (Quarterly) Benchmarks
| Merck & Co Inc | -2.814B |
| Axonics Inc | 0.248M |
| Johnson & Johnson | 546.00M |
| Boston Scientific Corp | 1.569B |
| Ambrx Biopharma Inc (DELISTED) | 9.71M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.53M |
| Cash from Investing (Quarterly) | -1.029M |
| Free Cash Flow | -69.50M |
| Free Cash Flow Per Share (Quarterly) | -4.210 |
| Free Cash Flow to Equity (Quarterly) | -16.62M |
| Free Cash Flow Yield | -81.57% |